

Cushing's Syndrome In Human

**Xavier Bertagna
Paris, March 2013**

**Cochin hospital, Faculté René Descartes
Université Paris 5**



CUSHING'S SYNDROME

- ! The clinical (and biochemical) features associated with chronic exposition to glucocorticoid excess**

Prevalence of clinical features of Cushing's syndrome^a
(prevalence of signs significantly different among patients with proven CS or without CS, in whom CS was suspected in a serie of 211 patients from Nugent)

	"	"CS	"	"W/O CS"
<u>Central obesity</u>	"	'0.90	"	'0.03"
<u>Generalized obesity</u>	"	'0.03	"	'0.62"
<u>Osteoporosis</u>	"	'0.64	"	'0.03"
<u>Weakness</u>	"	'0.65	"	'0.07"
<u>Ecchymosis</u>	"	'0.53	"	'0.06"
Serum K<3.6 mEq/l	"	'0.25	"	'0.04"
Plethora	"	'0.82	"	'0.31"
WBC > 11 000/mm ³	"	'0.58	"	'0.30"
Acne	"	'0.52	"	'0.24"
Striae (red, purple)	"	'0.46	"	'0.22"
Diastolic BP > 105	"	'0.39	"	'0.17"
Edema	"	'0.38	"	'0.17"
Hirsutism	"	'0.50	"	'0.29"
"				

Not different: oligomenorrhea, female, abnormal GTT"



CUSHING'S SYNDROME

- Diagnostic strategy -

THREE STEPS

-!Demonstrate chronic hypercortisolism

-!Establish its cause

-!Locate the responsible tumor

CUSHING'S SYNDROME

- Chronic hypercortisolism -

Three approaches :

-!Cortisol secretion is not normally suppressible.

-!Urinary cortisol is increased

-!Plasma (salivary) cortisol has lost its normal circadian variations


CUSHING'S SYNDROME



- Chronic hypercortisolism -

-!Cortisol secretion is not normally suppressible.

Suppression tests

- classic low dose dex suppression test (2 mg/day x 2 days)
- 1-mg overnight dex suppression test (1 mg dex at midnight)






Syndrome de Cushing

=

Tumeur Endocrine




Etiology of 809 Cushing's syndrome*



(Hôpital Cochin, 1992)

		"n= (%) "	"sex ratio (F/M)"
"			
<u>Cushing's Disease</u>	"	'548 (68 %)	" 2.8"
"			
<u>Ectopic ACTH syndrome*</u>	"	'58 (7%)"	" 1.4"
"			
<u>Primary adrenocortical tumor</u>	"199 (25 %)	"	" 4.2"
<i>Benign adenoma</i>	111 (14 %)		5
<i>Adrenocortical carcinoma</i>	88 (11 %)		3.6"
"			
"			
PPNAD'/AIMAH	"	"4 (0.4 %)	" -"
"			
"			


* Bronchial neuroendocrine tumor (BNT) well differentiated («!carcinoid!»): 30 %, undifferentiated BNT: 15 %, thymoma: 15%, pancreatic endocrine tumor: 15%, medullary cancer of the thyroid: 10%, pheochromocytoma: 5%, others 10%"





ACTH-dependent Cushing's syndrome

	<u>CLINICAL</u>	<u>ANATOMICAL</u>	<u>MOLECULAR</u>
	Typical « Silent »	Micro adenoma Macro adenoma (cancer)	- ? - ?
	Occult Aggressive	Carcinoid SCCL	- V3-R (legitimate !) - E2F

Micro adénome




Macro adénomes



Sécrétion Ectopique d' ACTH
Carcinoides bronchiques « occultes »

Cancer anaplasique du poumon avec Sécrétion ectopique d' ACTH



«ADRENAL» CUSHING'S SYNDROME

	<u>Adenoma</u>	- Sporadic, Isolated
	<u>Carcinoma</u>	- Sporadic, Isolated - Syndromic (BWS, LF)
	<u>PPNAD</u> (Primary Pigmented Nodular Adrenal Disease)	- Isolated - Familial,Syndromic (Carney Complex)
	<u>AIMAH</u> (ACTH Independent-Macronodular Adrenal Hyperplasia)	- Isolated - Familial - Syndromic (Mc Cune-Albright)


Adénome cortico surrénal



Adrenal cortical carcinoma



CT Scan
spontaneous density 27UH



PET Scan
18-FDG uptake





Carney complex"
The complex of myxomas, spotty pigmentation, and endocrine overactivity.
Medicine, 1985, J Aidan Carney"
PRKAR1A and 17q22-24 locus"

	Frequency
Spotty skin pigmentation	77 %
Skin Myxoma	33%
Cardiac Myxoma	53 %
PPNAD	26 %
Breast ductal adenoma	3 %
LCCST	33 % (male)
Thyroid tumor	5 %
Acromegaly	10 %
Melanocytic schwannoma	10 %

CA Stratakis, L Kirschner, JA Carney,
JCEM, 2001 (n= 338)


Primary Pigmented Nodular Adrenocortical Disease"

Introduction
Manifestations

- !Lentiginose 77 %

→ + fréquente
période péripubertaire
péri-orificielle


Lentiginose Hyperplasie
des mélanocytes

- !Lentiginose
- !Myxome cardiaque

77 % 53 % → pronostic vital
accident embolique


Cellule souche mesenchymateuse pluripotente

- !sujet jeune
- !toutes les cavités
- !récurrent





Matrice extracellulaire abondante



AI-MAH (ACTH Independent- Macronodular Adrenal Hyperplasia)



«ADRENAL» CUSHING'S SYNDROME

			<u>MOLECULAR</u>
◀ ◀		<u>Adenoma</u>	- Sporadic, Isolated - β -caténine - APC
◀		<u>Carcinoma</u>	- Sporadic, Isolated - Syndromic (BWS, LF) - IGFII, 17p13, ... - IGFII, p53
◀		<u>PPNAD</u> (Primary Pigmented Nodular Adrenal Disease)	- Isolated - Familial, Syndromic - PRKARIA - PDE11A4 (Carney Complex)
◀		<u>AI-MAH</u> (ACTH Independent- Macronodular Adrenal Hyperplasia)	- Isolated - Familial - Syndromic - « illegitimate Rs » - Gsa - APC (Mc Cune-Albright)





18FDG Pet scan in « advanced »ACC

